CTOs on the Move

Commonwealth Diagnostics International

www.commdx.com

 
Commonwealth Diagnostics International (CDI), Inc., was founded on the principle that preventative healthcare, including early detection and diagnosis of disease, results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Operating out of a newly constructed laboratory in Salem, MA, CDI is an international diagnostic service provider specializing in innovative diagnostic products that assist physicians and patients with the diagnosis and management of some of the world`s most common sources of digestive distress and functional gastrointestinal disorders, including: hydrogen (H2)/methane (CH4) breath testing for Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption, IBSchek™ for ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.commdx.com
  • 39 Norman Street
    Salem, MA USA 01970
  • Phone: 888.258.5966

Executives

Name Title Contact Details
Nathaniel Allen
 Director of Information Technology Profile

Similar Companies

Fisher Center for Alzheimers Research Foundation

Fisher Center for Alzheimers Research Foundation is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthnation

Healthnation, Inc. is a Lisle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMS Health Incorporated

MS Health has the dope on drugs. The company provides sales management and market research services to clients in the pharmaceutical and health care industries. It tracks not only the sale of prescription drugs and over-the-counter products but also the productivity of individual sales representatives that work for its client companies. It offers market forecasts and surveys to physicians and hospitals about drugs they are prescribing to patients. IMS Health also offers consulting and other professional services.

Hologram Sciences

Reimagining the future of nutrition

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.